Mirvetuximab soravtansine

Elahere 5 MG/ML Concentrado Para Solucion Para Perfusion

105,50 mg concentrado para solución para perfusiónSpainAuthorisedAuthorised 4 Dec 2024

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

ElahereEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Mirvetuximab soravtansine

Elahere 5 MG/ML Concentrado Para Solucion Para Perfusion

105,50 mg concentrado para solución para perfusiónSpainAuthorisedAuthorised 4 Dec 2024

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

ElahereEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Elahere Concentrate for Solution for Infusion 100MG/20MLSingapore · 100mg/20mL · infusion, solution concentrate · Abbvie Pte. LTD.

ElahereUnited States · 100mg/20mL single-dose vial · injectable · Immunogen INC

Packs

Pack	Code	Status
ELAHERE 5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 20 ml	766408

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Mirvetuximab soravtansine
Strength: 105,50 mg
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Authorised
Status in the register: Autorizado, no comercializado
Authorised: 4 Dec 2024
Registration: 1241866001
Marketing authorisation holder: Abbvie Deutschland Gmbh & Co. Kg
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/24/1866